shenggeletin

Shenggeletin (CT-053) is an investigational, orally active, highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor developed by Shengshi Taike Biopharmaceutical Technology (Centaurus Biopharma) for the treatment of type 2 diabetes mellitus. As a DPP-4 inhibitor, it prevents the inactivation of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This leads to increased insulin secretion and suppressed glucagon release in a glucose-dependent manner, thereby improving glycemic control. Shenggeletin is classified as a Class 1 innovative drug in China and has advanced into Phase 3 clinical trials, demonstrating potential as a potent and well-tolerated therapeutic option for patients with type 2 diabetes.

Other names

Shenggeletin phosphate圣格列汀